7.84
1.55%
0.12
시간 외 거래:
7.89
0.05
+0.64%
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily
Foghorn Therapeutics patents new CBP degradation inducers - BioWorld Online
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times
(FHTX) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World
Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance
Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat
HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) Q3 2024 Earnings: Revenue Surpas - GuruFocus.com
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire
(FHTX) Investment Report - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1% - MarketBeat
Long Term Trading Analysis for (FHTX) - Stock Traders Daily
Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance
Foghorn Therapeutics Announces First Patient Dosed with - GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - The Manila Times
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective - The Bakersfield Californian
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewswire
Perceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Perceptive Advisors LLC Buys New Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Foghorn Therapeutics' SWOT analysis: chromatin biology pioneer's stock outlook By Investing.com - Investing.com UK
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Holdings Increased by Rhumbline Advisers - Defense World
Deerfield Management Company L.P. Series C Takes Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com South Africa
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock - Investing.com India
(FHTX) Long Term Investment Analysis - Stock Traders Daily
Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2024 - MarketBeat
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Foghorn Therapeutics (NASDAQ:FHTX) Price Target Raised to $9.00 - MarketBeat
Market Insight: Foghorn Therapeutics Inc (FHTX)’s Notable Gain, Closing at 9.99 - The Dwinnex
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics exec sells over $116k in company stock - Investing.com India
Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics executive sells over $107k in company stock - Investing.com India
자본화:
|
볼륨(24시간):